We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$673M
AUM Growth
+$87.3M
Cap. Flow
+$52.4M
Cap. Flow %
7.78%
Top 10 Hldgs %
60.63%
Holding
55
New
16
Increased
9
Reduced
7
Closed
18

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$37.4M
2
EXEL icon
Exelixis
EXEL
+$24.9M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$20M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$16.9M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$32.9M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$17.3M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$15M
4
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$13.8M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 83.75%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.82B
$56.1M 8.34%
3,321,173
+1,321,173
+66% +$20M
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
$51.6M 7.66%
1,305,887
+128,768
+11% +$5.01M
KURA icon
3
Kura Oncology
KURA
$800M
$44.6M 6.63%
2,380,846
+183,563
+8% +$3.57M
PTCT icon
4
PTC Therapeutics
PTCT
$5.64B
$41.7M 6.19%
1,539,822
+454,022
+42% +$11.5M
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$39.2M 5.82%
978,302
-143,029
-13% -$5.67M
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$36.6M 5.44%
550,000
+139,100
+34% +$8.03M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.28B
$35.7M 5.3%
7,478,275
+2,726,392
+57% +$14M
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$35.6M 5.28%
736,631
-66,574
-8% -$3.71M
PBYI icon
9
Puma Biotechnology
PBYI
$404M
$34M 5.05%
+500,000
New +$37.4M
NBIX icon
10
Neurocrine Biosciences
NBIX
$16.8B
$33.2M 4.93%
400,000
– –
RIGL icon
11
Rigel Pharmaceuticals
RIGL
$681M
$30.4M 4.51%
857,945
+69,087
+9% +$2.77M
AIMT
12
DELISTED
Aimmune Therapeutics
AIMT
$28.7M 4.26%
900,579
+327,029
+57% +$11.5M
FOMX
13
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$24.5M 3.64%
4,781,708
– –
EXEL icon
14
Exelixis
EXEL
$13.3B
$19.9M 2.96%
+899,900
New +$24.9M
PRTA icon
15
CALL
Prothena Corp
PRTA
$425M
$18.4M 2.73%
+500,000
New +$18.2M
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$18.1M 2.68%
462,245
+289,121
+167% +$12.3M
NVCR icon
17
NovoCure
NVCR
$1.73B
$16.4M 2.44%
753,481
-125,805
-14% -$2.71M
FPRX
18
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$14.9M 2.21%
+868,100
New +$16.9M
ACHN
19
DELISTED
Achillion Pharmaceuticals
ACHN
$13.7M 2.04%
+3,700,000
New +$12.1M
ECYT
20
DELISTED
Endocyte, Inc. Common Stock
ECYT
$13.6M 2.01%
+1,491,500
New +$8.23M
SVRA icon
21
Savara
SVRA
$1.12B
$7.93M 1.18%
862,179
-7,321
-0.8% -$86.2K
CTIC
22
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$6.58M 0.98%
+1,687,020
New +$5.93M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
$6.44M 0.96%
2,695,742
-1,121,546
-29% -$3.73M
SRRA
24
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.44M 0.96%
+77,778
New +$8.82M
PTCT icon
25
CALL
PTC Therapeutics
PTCT
$5.64B
$5.41M 0.8%
+200,000
New +$5.07M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Great Point Partners held 55 positions worth $673M, up 15% from $586M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Great Point Partners deployed $52.4M of net new capital in Q1 2018, opening 16 new positions and adding to 9 existing holdings. Its largest new stake was Puma Biotechnology: 500,000 shares worth $34M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Lumos Pharma, Inc. Common Stock, an estimated $13.8M trimmed.

  • Great Point Partners's largest Q1 2018 buy was Puma Biotechnology: 500,000 shares worth $34M.
  • Great Point Partners added most to Iovance Biotherapeutics in Q1 2018, an estimated $20M increase.
  • Great Point Partners's biggest Q1 2018 reduction was Lumos Pharma, Inc. Common Stock, cutting an estimated $13.8M.
  • Great Point Partners fully exited Sage Therapeutics in Q1 2018, selling an estimated $32.9M.
  • Great Point Partners's ten largest holdings make up 61% of its $673M portfolio in Q1 2018.
  • Great Point Partners opened 16 new positions and closed 18 in Q1 2018.
  • Great Point Partners's portfolio value rose 15% quarter-over-quarter to $673M.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.